Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:


☐		Preliminary Proxy Statement

☐		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐		Definitive Proxy Statement

☒		Definitive Additional Materials

☐		Soliciting Material Under Rule 14a-12

DBV Technologies S.A.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):



☒	No fee required.

☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

	1)	Title of each class of securities to which transaction applies:

	2)	Aggregate number of securities to which transaction applies:

	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	4)	Proposed maximum aggregate value of transaction:

	5)	Total fee paid:

☐	Fee paid previously with preliminary materials.

☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:

	1)	Amount previously paid:

	2)	Form, Schedule or Registration Statement No:

	3)	Filing party:

	4)	Date Filed:

DBV TECHNOLOGIES - LIST OF CANDIDATES AS DIRECTORS AGM - MAY 19, 2021DBV TECHNOLOGIES - LIST OF CANDIDATES AS DIRECTORS AGM - MAY 19, 2021

JULIE O’NEILL Director Born on 25/02/1966 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette, 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) Director of HOOKIPA Pharma Inc. Director of National Institute for Bioprocessing Research and Training (NIBRT) Director, American Chamber of Commerce, Ireland Director, Icon plc Vice President Global Operations, Alexion Pharmaceuticals, Inc. Shareholding 9,000 « BSAX 2017 » giving the right to purchase 9,000 shares 7,000 « BSA 2018 » giving the right to purchase 7,000 sharesJULIE O’NEILL Director Born on 25/02/1966 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette, 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) Director of HOOKIPA Pharma Inc. Director of National Institute for Bioprocessing Research and Training (NIBRT) Director, American Chamber of Commerce, Ireland Director, Icon plc Vice President Global Operations, Alexion Pharmaceuticals, Inc. Shareholding 9,000 « BSAX 2017 » giving the right to purchase 9,000 shares 7,000 « BSA 2018 » giving the right to purchase 7,000 shares

VIVIANE MONGES Independent Director and Chair of the Audit Committee Born on 10/15/1963 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) VP Finance & Control at Nestlé Business Excellence, Director of Novo Holdings A/S, Director of Union Chimique Belge S.A. (UCB), Director of Idorsia Pharmaceuticals Ltd., Director of Voluntis S.A, Shareholding 600 shares directly heldVIVIANE MONGES Independent Director and Chair of the Audit Committee Born on 10/15/1963 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) VP Finance & Control at Nestlé Business Excellence, Director of Novo Holdings A/S, Director of Union Chimique Belge S.A. (UCB), Director of Idorsia Pharmaceuticals Ltd., Director of Voluntis S.A, Shareholding 600 shares directly held

ADORA NDU Independent Director Born on 04/18/1981 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) Group Vice President, Head of Worldwide Research & Development Strategy, Scientific Collaborations & Policy (SSCP) Vice President, Regulatory Affairs; Global Head of Regulatory Policy, Research, Engagement & International Adjunct Professor; Biotechnology Enterprise and Entrepreneurship Graduate Program at John Hopkins University Adjunct Professor; Health Services Management Program at University of Maryland, US Food & Drug Administration, Center for Drug Evaluation & Research, Director, Division of Medical Policy Development, Office of Medical Policy (OMP) Alliance for Regenerative Medicine; Board of Directors and Regulatory Affairs Committee Chair American Society for Gene and Cell Therapy (ASGCT) Regulatory Affairs Committee Chair. Shareholding N/AADORA NDU Independent Director Born on 04/18/1981 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) Group Vice President, Head of Worldwide Research & Development Strategy, Scientific Collaborations & Policy (SSCP) Vice President, Regulatory Affairs; Global Head of Regulatory Policy, Research, Engagement & International Adjunct Professor; Biotechnology Enterprise and Entrepreneurship Graduate Program at John Hopkins University Adjunct Professor; Health Services Management Program at University of Maryland, US Food & Drug Administration, Center for Drug Evaluation & Research, Director, Division of Medical Policy Development, Office of Medical Policy (OMP) Alliance for Regenerative Medicine; Board of Directors and Regulatory Affairs Committee Chair American Society for Gene and Cell Therapy (ASGCT) Regulatory Affairs Committee Chair. Shareholding N/A

RAVI RAO Independent Director Born on 11/21/1967 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) Head of Research & Development (Global) at Sobi Chief Medical Officer at Aeglea Biotherapeutics (AGLE) Vice President, Global Medical Affairs Head, Immunology and Specialty Medicine at GlaxoSmithKline (GSK) Research and Development Shareholding N/ARAVI RAO Independent Director Born on 11/21/1967 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) Head of Research & Development (Global) at Sobi Chief Medical Officer at Aeglea Biotherapeutics (AGLE) Vice President, Global Medical Affairs Head, Immunology and Specialty Medicine at GlaxoSmithKline (GSK) Research and Development Shareholding N/A

TIMOTHY E. MORRIS Independent Director and member of the Audit Committee Born on 10/06/1961 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) Chief Operating Officer and Chief Financial Officer at Humanigen Director, Chair of the Audit Committee and member of the Compensation Committee at Humanigen Chief Financial Officer at Iovance Biotherapeutics Chief Financial Officer at AcelRx Shareholding N/ATIMOTHY E. MORRIS Independent Director and member of the Audit Committee Born on 10/06/1961 Business address : DBV Technologies, 177/181 avenue Pierre Brossolette 92120 Montrouge (France) Other mandates and positions exercised in the last five years (excluding DBV Technologies) Chief Operating Officer and Chief Financial Officer at Humanigen Director, Chair of the Audit Committee and member of the Compensation Committee at Humanigen Chief Financial Officer at Iovance Biotherapeutics Chief Financial Officer at AcelRx Shareholding N/A

DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Mar 2024 to Apr 2024